Panelists discuss how the data from the BRAVE-AA1 and BRAVE-AA2 phase 3 trials demonstrated the safety and efficacy of baricitinib, leading to its FDA approval in 2022 as the first systemic treatment ...

Recent clinical trials have shown promising results for JAK inhibitors in treating alopecia areata. For instance, two phase 3 trials of baricitinib, a selective JAK1 and JAK2 inhibitor ...

Mayo Clinic researchers have identified a targeted therapy that could bring relief to people living with lichen planus, a ...

It is estimated that there are around 300,000 people in the US with severe alopecia that could be eligible for treatment with Olumiant (baricitinib), said the agency. In trials, patients who had ...

Olumiant (baricitinib) is a prescription drug used to treat severe alopecia areata. It’s typically used when hair loss from this condition affects more than 50% of the scalp. Olumiant is a brand ...

Within the baricitinib group, patients experienced a mean Vitiligo Area Scoring Index score change of 44.8% from baseline to week 36. In contrast, the placebo group saw a 9.2% change. The Janus ...

LEO Pharma, Eli Lilly and Company, and others .Key Alopecia Areata Therapies: OLUMIANT (baricitinib), LITFULO (ritlecitinib), Etrasimod, Coacillium (LH-8), PF-06651600, ADX-914, Upadacitinib ...

Baricitinib can effectively treat polymyalgia rheumatica (PMR) without the use of oral glucocorticoids, according to results from a small, randomized, double-blind, placebo-controlled study.

So, as I mentioned, oral minoxidil is something that even alone can show benefit in alopecia areata ... And so, for baricitinib baseline labs, we want to check a blood count, liver function ...